Bli medlem
Bli medlem

Du är här

2021-07-07

BioStock: WntResearch reaches full operations again in NeoFox study

The NeoFox study, conducted to explore the efficacy of WntResearch's drug candidate Foxy-5, is now back in full swing. A total of 80 patients have been recruited and the company reiterates that it sees good opportunities to obtain an interim result from the study by the end of 2022. BioStock has spoken to Anders Rabbe, CEO of WntResearch, to get his view on the latest news.

Read the full article at biostock.se:
https://www.biostock.se/en/wntresearch-reaches-full-operations-again-in-neofox-study/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Författare Cision

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.